Overview

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of bifeprunox or risperidone on the body weight of patients with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator:
Solvay Pharmaceuticals
Treatments:
Risperidone